Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer
Targeting the prostate-specific membrane antigen (PSMA) protein has become of great clinical value in prostate cancer (PCa) care. PSMA positron emission tomography/computed tomography (PET/CT) is increasingly used in initial staging and restaging at biochemical recurrence in patients with PCa, where...
Main Authors: | Wietske I. Luining, Matthijs C. F. Cysouw, Dennie Meijer, N. Harry Hendrikse, Ronald Boellaard, André N. Vis, Daniela E. Oprea-Lager |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/5/1169 |
Similar Items
-
Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers
by: Wietske I. Luining, et al.
Published: (2021-01-01) -
Pharmacological Optimization of PSMA-Based Radioligand Therapy
by: Suzanne van der Gaag, et al.
Published: (2022-11-01) -
PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
by: Wallace Jones, et al.
Published: (2020-05-01) -
Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
by: Chalermrat Kaewput, et al.
Published: (2022-05-01) -
The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer—A Practical Clinical Review
by: Anna Rebecca Lisney, et al.
Published: (2022-07-01)